Finance

Lists
Why is AVH up 2,16%?
Dive Deeper
AVH:ASX
AVITA Medical Inc
3,78 AUD
+2,16%
(+0,080) 1D
20-окт., 16:10:24 GMT+11  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for AVH...
Open
3,72 AUD
High
3,82 AUD
Low
3,72 AUD
Mkt. cap
593,33 млн
Avg. vol.
332,46 миң
Volume
136,10 миң
52-wk high
3,91 AUD
52-wk low
1,00 AUD
Shares outstanding
30,93 млн
No. of employees
226
Open
3,72 AUD
High
3,82 AUD
Low
3,72 AUD
Mkt. cap
593,33 млн
Avg. vol.
332,46 миң
Volume
136,10 миң
52-wk high
3,91 AUD
52-wk low
1,00 AUD
Shares outstanding
30,93 млн
No. of employees
226
News stories
From web sources and news partners
Profile
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts. Wikipedia
About AVITA Medical Inc
CEOJames Corbett
Employees226
Founded1999
HeadquartersВаленсия, Калифорния, Америка Кошмо Штаттары
Sector-
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
-0,36 AUD / -0,42 AUD
+15,38%beat
Revenue / Est. (AUD)
30,85 млн / 28,70 млн
+7,49%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
17,06 млн
17,62 млн
19,25 млн
21,70 млн
Cost of goods sold
3,19 млн
3,30 млн
3,52 млн
3,94 млн
Cost of revenue
3,19 млн
3,30 млн
3,52 млн
3,94 млн
Research and development expenses
3,75 млн
5,69 млн
5,63 млн
5,08 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19,28 млн
19,03 млн
18,90 млн
19,54 млн
Operating expense
23,03 млн
24,72 млн
24,53 млн
24,62 млн
Total operating expenses
26,22 млн
28,02 млн
28,05 млн
28,56 млн
Operating income
-9,15 млн
-10,41 млн
-8,80 млн
-6,86 млн
Other non operating income
49,00 миң
737,00 миң
-95,00 миң
-12,00 миң
EBT including unusual items
-13,17 млн
-11,64 млн
-10,62 млн
-7,63 млн
EBT excluding unusual items
-12,27 млн
-11,04 млн
-10,32 млн
-7,83 млн
Income tax expense
15,00 миң
-17,00 миң
-11,00 миң
33,00 миң
Effective tax rate
-0,11%
0,15%
0,10%
-0,43%
Other operating expenses
-
-
-
-
Net income
-13,19 млн
-11,62 млн
-10,61 млн
-7,66 млн
Net profit margin
-77,29%
-65,97%
-55,12%
-35,31%
Earnings per share
-
-
-
-
Interest and investment income
300,00 миң
200,00 миң
-
500,00 миң
Interest expense
-3,47 млн
-1,55 млн
-1,42 млн
-1,46 млн
Net interest expenses
-3,17 млн
-1,35 млн
-1,42 млн
-963,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-8,58 млн
-9,76 млн
-8,18 млн
-6,25 млн
Gain or loss from assets sale
252,00 миң
5,00 миң
55,00 миң
188,00 миң
AI content may include mistakes. Learn more
Google колдонмолору